

# Anti-inflammatory sesquiterpenes from *Curcuma zedoaria*

H. MAKABE,<sup>\*</sup> † N. MARU, ‡ A. KUWABARA, ‡ T. KAMO, ‡ and M. HIROTA<sup>‡</sup>

<sup>†</sup>*Sciences of Functional Foods, Graduate School of Agriculture, Shinshu University,*

*Minami-minowa, Kami-ina, Nagano 399-4598, Japan*

<sup>‡</sup>*Department of Bioscience and Biotechnology, Faculty of Agriculture, Shinshu University,*

*Minami-minowa, Kami-ina, Nagano 399-4598, Japan*

\*To whom correspondence should be addressed.

From the methanolic extract of the rhizome of *Curcuma zedoaria*, we isolated anti-inflammatory sesquiterpene furanodiene (**1**) and furanodienone (**2**) along with new sesquiterpene compound **3** and known eight sesquiterpenes, zederone (**4**), curzerenone (**5**), curzeone (**6**), germacrone (**7**), 13-hydroxygermacrone (**8**), dehydrocurdione (**9**), curcumenone (**10**), and zedoaronediol (**11**). Their structures were elucidated on the basis of spectroscopic data. The anti-inflammatory effect of isolated components on 12-*O*-tetradecanoylphorbol-13- acetate (TPA)-induced inflammation of mouse ears were examined. Compounds **1** and **2** suppressed TPA-induced inflammation of mouse ears by 75% and 53%, respectively, at a dose of 1.0  $\mu\text{mol}$ . Their activities are comparable to that of indomethacin, the normally used anti-inflammatory agent.

*Keywords:* anti-inflammatory; *Curcuma zedoaria*; 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-induced edema

Zedoary (*Curcuma zedoaria* Roscoe, Zingiberaceae) is cultivated as a vegetable, spice, and perfumery material in Southeast Asian countries. The rhizome of this plant has been used as a stimulant, stomachic, carminative, diuretic, anti-diarrheal, anti-emetic, anti-pyretic, and depurator, and also as an ointment for ulcers, wounds, and other skin disorders.<sup>1)</sup> Recently, Yoshikawa *et al* have revealed that chemical constituent of *C. zedoaria* showed vasorelaxant, hepatoprotective, and inhibitory activity of NO production.<sup>2)-4)</sup> The zedoary is used to the treatment of the skin disease, however the study of the anti-inflammatory effect of chemical constituents from *C. zedoaria* has not been studied so far except that of dehydrocurdione (**9**) by Yoshioka *et al.*<sup>5)</sup> Therefore, we tried to isolate sesquiterpens from zedoary and subject on anti-inflammatory test. For isolating sesquiterpens like dehydrocurdione, we used the reddish spot on thin layer chromatography with spraying of anisaldehyde/sulfuric acid as index.


In the present paper, we describe the structure of isolated eleven sesquiterpenes from *C. zedoaria* and their anti-inflammatory effect on the 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-induced edema of mouse ears.

The zedoary rhizome (cultivated in Okinawa, Japan) was soaked in methanol, and the resulting methanol extract was concentrated *in vacuo*. The concentrate was successively partitioned between benzene and water, and then ethyl acetate and water. The benzene-soluble part showed anti-inflammatory activity (IE of 34% at a dose of 2 mg). The benzene-soluble part was chromatographed on silica gel to give 20% ethyl

acetate in hexane eluate as an active fraction. Further purification with preparative thin layer chromatography gave compounds **1** and **2** as anti-inflammatory compounds. Spectral analysis of **1** and **2** were indicative to be furanodiene<sup>6)</sup> and furanodienone,<sup>7)</sup> respectively. Comparison of the spectral data of **1** and **2** with the reference data confirmed the structure of **1** and **2**.

Compounds **1**, **2**, and **5-7** were also isolated from 20% ethyl acetate in hexane eluate and identified as germacrane type sesquiterpene, curzerenone (**5**),<sup>8)</sup> curzeone (**6**),<sup>9)</sup> germacrone (**7**).<sup>10)</sup> From 30% EtOAc in hexane eluate gave dehydrocurdione (**9**),<sup>11)</sup> 40% EtOAc in hexane eluate gave zederone (**4**),<sup>12)</sup> and curcumenone (**10**),<sup>13)</sup> and 50% EtOAc in hexane eluate afforded 13-hydroxygermacrone (**8**).<sup>9)</sup> The EtOAc soluble part afforded zedoaronediol (**11**).<sup>14)</sup>

These constituents (**4-11**) were identified by comparison of their physical and spectral data with reported values (Figure 1).<sup>8)-14)</sup>



**Fig. 1.** Sesquiterpenes from *Curcuma zedoaria*


Compound **3** was newly isolated compound. The HR-EIMS analysis of **3** gave the molecular formula of  $C_{15}H_{18}O_2$  ( $m/z$  230.1285) which showed same molecular formula that of **2**. The IR spectrum of **3** showed the presence of an  $\alpha$ ,  $\beta$ -unsaturated carbonyl group ( $1682\text{ cm}^{-1}$ ). The  $^{13}\text{C}$ -NMR spectrum of **3** showed a signal assignable to carbonyl group ( $\delta$  200.0) and eight signals due to four  $\text{C}=\text{C}$  bonds ( $\delta$  152.9-117.1), suggesting that **3** was a bicycle compound. Signals assignable to two methyl groups ( $\delta$

1.61 and 1.94), four methylene groups ( $\delta$  3.38, 3.38, 2.33, and 2.25), an *exo*-methylene group ( $\delta$  5.06 and 4.91, each 1H), and two methine groups ( $\delta$  7.01 and 5.40) were observed in the  $^1\text{H}$ -NMR spectrum of **3** (Table 1).

**Table 1.**  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR Data for **3**

position	$^{13}\text{C}$		$^1\text{H}$
1	130.8	CH	5.40, (1H, dd, $J = 7.8, 7.2$ Hz)
2	28.5	$\text{CH}_2$	2.25, (2H, m)
3	35.1	$\text{CH}_2$	2.33, (2H, br.s)
4	142.3	C	
5	52.9	$\text{CH}_2$	3.38, (2H, br.s)
6	200.0	C	
7	119.5	C	
8	152.9	C	
9	38.3	$\text{CH}_2$	3.38, (2H, br.s)
10	131.5	C	
11	125.7	C	
12	137.5	CH	7.01, s
13	8.6	$\text{CH}_3$	1.94, s
14	117.1	$\text{CH}_2$	4.91, s 5.06, s
15	17.2	$\text{CH}_3$	1.61, s

Making comparison of the  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR data between **2** and **3**, compound **2** has an *exo*-methylene moiety and lacks of one methyl group. This compound is an isomer of **2**, in the structure of which one of the C=C bond is located between C-4 and C-5 by an analysis of the H-H COSY, and HMBC spectra of **3** (Figure 2).



**Fig. 2.** H-H COSY and HMBC correlation of **3**

Compounds **1-11** were subjected to the mouse ear anti-inflammatory test. As shown in Table 2, **1** and **2** suppressed TPA-induced inflammation by up to 75% and 53%, respectively, at a dose of 1  $\mu\text{mol}$  application. Among the furan containing germacrane type sesquiterpenes, furanodiene (**1**) and furanodienone (**2**) showed potent

anti-inflammatory activity. Oxidized compound **4** and compound **3** which possesses *exo*-methylene moiety lost the activity.

**Table 2.** Anti-inflammatory Activities of **1-11** in the Mouse Ear Inflammatory Test

Test compound	Inhibitory effect (IE %)
<b>1</b>	75 (± 0.9)**
<b>2</b>	53 (± 1.3)**
<b>3</b>	9 (± 1.1)
<b>4</b>	2 (± 0.7)
<b>5</b>	-2 (± 0.8)
<b>6</b>	18 (± 1.2)
<b>7</b>	7 (± 1.0)
<b>8</b>	9 (± 0.4)**
<b>7</b>	-2 (± 1.2)
<b>9</b>	16 (± 2.4)
<b>11</b>	17 (± 1.4)
indomethacin*	78 (± 0.8)**

In parentheses: A sample (1.0 µmol) was applied on one mouse ear and, after 30 min, TPA (0.5 mg) was applied to both ears of the mouse. The edema was evaluated after 7 hr, the inhibitory effect being expressed as the percentage ratio of the edema. Five mice were used for each experiment. \*1.4 µmol was applied. \*\*Significantly different,  $P < 0.05$  in the Student's t-test.

Dehydrocurdione (**9**) was reported to inhibit acute inflammation of rat paw induced by carrageenan injection. However, **9** did not show anti-inflammatory activity on TPA-induced mouse ear edema at a dose of 1 µmol per ear. Compound **5-8**, **10**, and **11** did not show any inhibitory activity on mouse ear edema.

**1** and **2** exhibited anti-inflammatory effect on TPA-induced mouse ear edema. This is the first finding of germacrane type sesquiterpenes showed anti-inflammatory activity. The activity is comparable to that of indomethacin, the normally used anti-inflammatory agent. The isolated amount of **2** is quite large. This may be important evidence substantiating traditional effect of this herbal medicine for the treatment of wounds and skin disorders.

## EXPERIMENTAL

The mass spectra were obtained using a Jeol JMS-700 mass spectrometer. The IR spectra were recorded on a Jasco FT/IR-480 Plus IR spectrometer. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on a Bruker DRX-500 FT-NMR spectrometer operating at 500.1 MHz for the protons and at 125.8 MHz for carbons, with TMS as the internal standard.

### Extraction and isolation

Fresh rhizomes of *C. zedoaria* (3.6 kg) were extracted with MeOH, and the extract was concentrated *in vacuo*. The aqueous solution was successively partitioned with benzene/water and EtOAc/water. Benzene and EtOAc soluble portions yielded 7.8 g and 0.6 g, respectively.

### Isolation of 1-10

Benzene-soluble portion (7.8 g) was chromatographed in a silica gel (400 g) column with EtOAc/hexane by 10% stepwise elution. The 20% EtOAc/hexane eluate (1.6 g) was further purified with preparative TLC to afford furanodiene (**1**, 8 mg), furanodienone (**2**, 384 mg), compound **3** (8 mg), curzerenone (**5**, 4 mg), curzeone (**6**, 7 mg), germacrone (**7**, 10 mg). As the same method described above, the 30% EtOAc/hexane eluate (3.4 g) afforded dehydrocurdione (**9**, 33 mg), the 40% EtOAc/hexane eluate (0.88 g) afforded zedrone (**4**, 70 mg) and curcumenone (**10**, 110 mg), and the 50% EtOAc/hexane eluate (0.28 g) furnished 13-hydroxygermacrone (**8**, 22 mg).

### Isolation of 11

EtOAc soluble portion (0.6 g) was chromatographed in a silica gel (30 g) column with hexane/EtOAc by 10% stepwise elution. The 70% EtOAc/hexane eluate (25 mg) was further purified with preparative TLC to afford zedoaronediol (**11**, 20 mg).

**Furanodiene (1).** <sup>1</sup>H-NMR (CDCl<sub>3</sub>, Me<sub>4</sub>Si) δ: 1.27 (3H, s), 1.60 (3H, s), 1.92 (3H, s), 1.76-2.30 (4H, m), 3.07 (2H, m), 3.43-3.56 (2H, m), 4.74 (1H, t, *J* = 7.2 Hz), 4.94 (1H, m), 7.07 (1H, s). <sup>13</sup>C-NMR (CDCl<sub>3</sub>, Me<sub>4</sub>Si) δ: 8.90, 16.21, 16.47, 24.36, 26.83, 39.49, 40.93, 118.89, 121.89, 127.60, 128.80, 129.04, 134.36, 135.98, 149.73.

**Furanodienone (2).** <sup>1</sup>H-NMR (CDCl<sub>3</sub>, Me<sub>4</sub>Si) δ: 1.30 (3H, s), 1.99 (3H, s), 2.13 (3H, s), 1.85-2.49 (4H, m), 3.70 (2H, m), 5.17 (1H, m), 5.81 (1H, s), 7.07 (1H, s). <sup>13</sup>C-NMR (CDCl<sub>3</sub>, Me<sub>4</sub>Si) δ: 9.56, 15.80, 18.99, 26.47, 40.70, 41.74, 122.24, 123.78, 130.57, 132.49, 135.44, 138.11, 145.74, 156.53, 189.81.

**Compound 3.** Colorless resin. HREIMS *m/z* (M<sup>+</sup>): calcd: for C<sub>15</sub>H<sub>18</sub>O<sub>2</sub>, 230.1307; found, 230.1285. EIMS *m/z* (rel. int.): 230 [M<sup>+</sup>] (77), 215 (47), 175 (93), 163 (100), 122 (90). IR ν<sub>max</sub>(film) cm<sup>-1</sup>: 3074, 2926, 2856, 1683, 1640, 1375, 897, 752. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR data are shown in Table 1.

### **Anti-inflammatory test.**

Mouse inflammatory tests were conducted by Gshwendt's method.<sup>15)</sup> TPA was purchased from Sigma Chemical Co. This experiment complied with the regulations concerning animal experimentation and the care of experimental animals of the Faculty of Agriculture at Shinshu University.

### **Acknowledgements**

The authors thank Mr. Kiyoshi Sato of Kinjirushi Co. Ltd., (Nagoya) for kind supply for zedoary. The financial support from Kinjirushi Co. Ltd., (Nagoya) is acknowledged. The authors also thank Ms. M. Miyazawa for measuring the NMR spectra.

### **References**

- [1] Matthes, H. W., Luu, B., and Ourisson, G. *Phytochemistry*, **19**, 2643-2650 (1980).
- [2] Matsuda, H., Morikawa, T., Ninomiya, K., and Yoshikawa, M. *Tetrahedron*, **57**, 8443-8453 (2001).
- [3] Matsuda, H., Morikawa, T., Ninomiya, K., and Yoshikawa, M. *Bioorg. Med. Chem.*, **9**, 909-916 (2001).
- [4] Matsuda, H., Morikawa, T., Toguchida, I., Ninomiya, K., and Yoshikawa, M. *Chem. Pharm. Bull.*, **49**, 1558-1566 (2001).
- [5] Yoshioka, T., Fujii, E., Endo, M., Wada, K., Tokunaga, Y., Shiba, N., Hosho, H., Shibuya, H., and Muraki, T. *Inflamm. Res.*, **47** 476-481 (1998).
- [6] Hikino, H., Agatsuma, K., and Takemoto, T. *Tetrahedron Lett.*, 931-933 (1968).
- [7] Hikino, H., Konno, C., and Takemoto, T. *Chem. Commun.*, 662-663 (1969).
- [8] Hikino, H., Agatsuma, K., and Takemoto, T. *Tetrahedron Lett.*, 2855-2858 (1968).
- [9] Shiobara, Y., Asakawa, Y., Kodama, M., and Takemoto, T., *Phytochemistry*, **25**, 1351-1353 (1986).
- [10] Hikino, H., Konno, C., Nagashima, T., Kohama, T., and Takemoto, T. *Tetrahedron Lett.*, 337-340 (1971).
- [11] Hikino, H., Konno, C., and Takemoto, T. *Chem. Pharm. Bull.*, **20**, 987-989 (1972).
- [12] Hikino, H., Takahashi, S., Takemoto, T., and Bhacca, N. S. *Chem. Pharm. Bull.*, **16**, 1081-1087 (1968).
- [13] Shiobara, Y., Asakawa, Y., Kodama, M., Yasuda, K., and Takemoto, T. *Phytochemistry*, **24**, 2629-2633 (1985).
- [14] Kuroyanagi, M., Ueno, A., Ujiie, K., and Sato, S. *Chem. Pharm. Bull.* **35**, 53-59 (1987).
- [15] Gschwendt, M., Kittstein, W., Furstenberger, G., and Marks, F. *Cancer Lett.*, **25**, 177-185 (1984)